Absci (ABSI) and Its Competitors Head-To-Head Survey
Absci (NASDAQ:ABSI – Get Rating) is one of 40 publicly-traded companies in the “Commercial physical research” industry, but how does it contrast to its peers? We will compare Absci to related businesses based on the strength of its profitability, institutional ownership, valuation, analyst recommendations, risk, dividends and earnings.
profitability
This table compares Absci and its peers’ net margins, return on equity and return on assets.
| net margins | return on equity | return on assets | |
| absci | -2,633.14% | -36.19% | -22.99% |
| Absci Competitors | -260.35% | -8.17% | -2.92% |
Institutional & insider ownership
40.0% of Absci shares are held by institutional investors. Comparatively, 59.5% of shares of all “Commercial physical research” companies are held by institutional investors. 11.4% of shares of all “Commercial physical research” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Valuation and Earnings
This table compares Absci and its peers gross revenue, earnings per share (EPS) and valuation.
| Gross revenue | Net Income | Price/earnings ratio | |
| absci | $4.78 million | -$100.96 million | -1.13 |
| Absci Competitors | $2.80 billion | $97.54 million | 12.81 |
Absci’s peers have higher revenue and earnings than Absci. Absci is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Analyst Ratings
This is a summary of current ratings and price targets for Absci and its peers, as provided by MarketBeat.com.
| sell ratings | hold ratings | Buy rating | Strong Buy Ratings | rating score | |
| absci | 1 | 3 | 3 | 0 | 2.29 |
| Absci Competitors | 39 | 576 | 1184 | 22 | 2.65 |
Absci currently has a consensus price target of $20.40, indicating a potential upside of 444.00%. As a group, “Commercial physical research” companies have a potential upside of 58.33%. Given Absci’s higher probable upside, equities research analysts clearly believe Absci is more favorable than its peers.
Summary
Absci peers beat Absci on 11 of the 12 factors compared.
About Absci (Get Rating)
Absci Corporation, a drug and target discovery company, provides biologic drug candidates and production cell lines using integrated drug creation platform for partners in the United States. Its integrated drug creation platform enables the creation of biologics by unifying the drug discovery and cell line development processes into one process. Absci Corporation was founded in 2011 and is headquartered in Vancouver, Washington.
Receive News & Ratings for Absci Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Absci and related companies with MarketBeat.com’s FREE daily email newsletter.